Additionally, early data from the ongoing PD-L1 Expression in Cancer (PECan) clinical trial (NCT04436406) demonstrated an association between high baseline PD-L1 expression, determined by [99mTc]NM-01 SPECT/CT, and 9-week ICI-treatment response in advanced NSCLC [10]. The gene discussed is CD274; the disease is cancer.